Business Wire

Carbon Trade eXchange (CTX) Partners With Victoria Falls Carbon Registry & Exchange in Zimbabwe: ‘Making Lemonade out of Lemons’

13.7.2023 20:49:00 EEST | Business Wire | Press release

Share

History was made in Victoria Falls Zimbabwe, on July 7th, 2023, the final day of the inaugural Africa Voluntary Carbon Credits Forum (AVCCM). Agreements were signed to initiate and install a Regional (Pan African) Carbon Registry owned and operated in Zimbabwe plus a locally operated, owned, and branded version of the worlds first and leading global Voluntary Carbon platform, Carbon Trade Exchange (CTX).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230713321840/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Contracts Signed in Victoria Falls Zimbabwe (Photo: Business Wire)

The Victoria Falls Carbon Registry (VFCR) will support the migration of Zimbabwe and other African nations projects and Carbon Credits back to Africa to be re-issued under their control. African Nations wishing to participate will be offered a National Sub-license and Registry Administration role within the VFCR, to support, lodge, monitor and manage projects and credit issuance in their nation. This low-cost solution negates the need for separate National Registries. Project types, methodologies and registry fees will be at the discretion of the VFCR, and they expect support from existing carbon credit standards internationally. The Registry will be operational in August 2023 and will start accepting projects, new or migrating, as soon as staff are trained to do so. Global Environmental Markets Group (GEM) will deliver the technology with training in August.

The Victoria Falls Carbon Exchange (VFCX) will have immediate access via CTX to hundreds of projects worldwide for buyers globally, millions of credits listed across worldwide for T+0 clearance and settlement. Plus new credits issued by VFCR Registry listed on the VFCX /CTX globally) instantly at the price the seller determines from that new registry. VFCX registry account holders can list via VFCX at no costs to list. A 5% fee on Sale of credits, no transfer or Retirement fees.

The AVCCM event attracted a large global audience across the carbon market, plus Government, banking, and project developers, supporting Zimbabwean Government’s decision to bring the carbon credits ‘home’ under the UNFCCC Paris Agreement.

“This is the future Africa said it wanted from the Paris agreement in 2015,” according to Wayne Sharpe, CEO & Founder, Global Environmental Markets Group. This follows on from COP27 where GEM and CTX did multiple presentations to various African nations. After speaking at the AVCCM event, Wayne added, “We saw the passion and commitments to Carbon Credits in Zimbabwe and Africa. This is why we built this technology, to deliver financial and ecological benefits to nations on the ground! ”

Kwanele Hlabangana, Chairman and Co-Founder of AVCCM said, “Partnering with experienced world class Carbon Market technology leaders like GEM & CTX is exciting. Responses from projects, communities and governments is outstanding. It's a great opportunity to accelerate Africa into the Global Climate to save our planet.” Ground up approach plus community engagement combined with GEM’s proven world class Registry and Exchange technology ticks the boxes for a trusted, credible, transparent, and vibrant African marketplace

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

CTX/GEM:
Wayne Sharpe,
CEO and Founder
info@ctxglobal.com
+44 7502 229523,
www.ctxglobal.com
www.gemglobal.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye